Phosplatin Therapeutics is harnessing immunogenic cell death (ICD) as an alternative mechanism to existing cancer immunotherapy strategies. PT-112, Phosplatin’s lead ICD inducer, is in phase 2 ...

Therefore, it is desirable to perform more extensive histocompatibility testing for the most immunogenic organs, but the length of cold ischemia time an organ will tolerate limits the extent of ...